mulTiplex Immunoassay qualiTy assuRance Panel (TITRE)
Development of Group B Streptococcus Quality Assurance Panel for the GASTON Multiplex Anti-CPS IgG Immunoassay.
연구 개요
상세 설명
This is a single-visit study designed to collect serum samples from women who previously participated in the GBS6 clinical trial, "A placebo-controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants" (GBS6 trial). The purpose of this follow-up study is to obtain serum samples for the development of Quality Control Sera (QCS) and Assay Bridging (AB) panels to support long-term quality control and performance monitoring of the GASTON immunoassay.
The GBS6 trial enrolled 300 pregnant women between October 2022 and July 2023 at Kawempe National Referral Hospital and Kisenyi Health Centre IV. The last participant completed follow-up on 23 October 2024. Of these, 150 participants (75 living with HIV and 75 not living with HIV) were randomized to receive either the GBS6 vaccine or placebo (normal saline). The GBS6 vaccine is a capsular polysaccharide conjugate vaccine targeting the six most common disease-causing GBS serotypes.
For this follow-up study, only participants who received the GBS6 vaccine and are not living with HIV (n=75) will be contacted via telephone using the contact details provided in the GBS6 trial records. Each consenting participant will attend a single study visit for serum collection. Collected samples will be shipped to the City, St George's laboratory for antibody screening. The GASTON assay will measure IgG concentrations for serotypes Ia, Ib, II, III, IV, and V. Based on these results, samples will be ranked by IgG values, and an appropriate pooling strategy will be developed to generate the QCS and AB panels.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Madeleine Cochet
- 전화번호: +442087255214
- 이메일: mcochet@sgul.ac.uk
연구 연락처 백업
- 이름: Mary Kyohere
- 전화번호: +447490390327
- 이메일: mkyohere@sgul.ac.uk
연구 장소
-
-
-
Kampala, 우간다
- 모병
- MUJHU Care Ltd, Kampala
-
연락하다:
- Zakaria Mukasa, Dr
- 전화번호: +256 782 201308
- 이메일: zmukasa@mujhu.org
-
수석 연구원:
- Robert Mboizi
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- HIV-uninfected women who received the GBS6 vaccine during pregnancy and completed the whole period of study participation.
- Reachable by phone
- Willing and able to provide consent.
- Willingness to provide a blood sample.
Exclusion Criteria:
- Receipt of blood/plasma transfusion in the last 3 months
- Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids.
- Women who will test positive for Syphilis or HIV at screening
- Current alcohol abuse or illicit drug use, or with a psychiatric condition
- Major illness of the mother that, in the investigator's judgment, will substantially increase the risk associated with the participant's participation in the study, including but not limited to the following:
I. heart disease II. severe anaemia (Hemoglobin level less than 7.0g/dL)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Women not living with HIV, who received the GBS6 vaccine GBS6 Clinical Trial in Kampala, Uganda
Women not living with HIV, who received the GBS6 vaccine in the "a placebo-controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants" (GBS6) Clinical Trial in Kampala, Uganda. The GBS6 trial enrolled 300 pregnant women between October 2022 and July 2023. Of these, 150 participants (75 living with HIV and 75 not living with HIV) were randomized to receive either the GBS6 vaccine (a capsular polysaccharide conjugate vaccine targeting the six most common disease-causing GBS serotypes) or placebo (normal saline). For this follow-up study, only participants who received the GBS6 vaccine and are not living with HIV (n=75) will be contacted via telephone using the contact details provided in the GBS6 trial records. Each consenting participant will attend a single study visit for serum collection. |
50mls of blood will be collected from all participants who give consent.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Creation of a quality control and bridging panels for the GBS multiplex immunoassay (GASTON assay)
기간: 1 year
|
Approx 50mL of blood will be collected from each study participant and will be used only for the development of QCS and AB panels.
Blood samples will be processed and serum stored at -20C in Kampala, Uganda.
The serum will be transferred to the City St George's, University of London laboratory, in the United Kingdom (UK), where the serum will be assayed for GBS6 serotype-specific anti-capsular antibodies using the GASTON multiplex anti-CPS IgG immunoassay.
Concentrations of anti-capsular IgG for the 6 serotypes (Ia, Ib, II, III, IV, and V) will be determined and a serum pooling strategy developed to produce a QCS panel consisting of three samples that span high, medium and low IgG values for each serotype and a 22- member bridging panel that will span the range of the assay for all serotypes.
The QC panels will be distributed to members of the GASTON consortium for the purpose of assay performance monitoring until they are depleted.
|
1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kirsty Le Doare, City St George's, University of London
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SE0306
- INV-087236 (기타 보조금/기금 번호: Gates Foundation)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .